544 related articles for article (PubMed ID: 33314079)
1. Efficacy, tolerability, and safety of eptinezumab in patients with a dual diagnosis of chronic migraine and medication-overuse headache: Subgroup analysis of PROMISE-2.
Diener HC; Marmura MJ; Tepper SJ; Cowan R; Starling AJ; Diamond ML; Hirman J; Mehta L; Brevig T; Sperling B; Cady R
Headache; 2021 Jan; 61(1):125-136. PubMed ID: 33314079
[TBL] [Abstract][Full Text] [Related]
2. Preventive migraine treatment with eptinezumab reduced acute headache medication and headache frequency to below diagnostic thresholds in patients with chronic migraine and medication-overuse headache.
Marmura MJ; Diener HC; Cowan RP; Tepper SJ; Diamond ML; Starling AJ; Hirman J; Mehta L; Brevig T; Cady R
Headache; 2021 Oct; 61(9):1421-1431. PubMed ID: 34551130
[TBL] [Abstract][Full Text] [Related]
3. Quantity changes in acute headache medication use among patients with chronic migraine treated with eptinezumab: subanalysis of the PROMISE-2 study.
Cowan RP; Marmura MJ; Diener HC; Starling AJ; Schim J; Hirman J; Brevig T; Cady R
J Headache Pain; 2022 Sep; 23(1):115. PubMed ID: 36068494
[TBL] [Abstract][Full Text] [Related]
4. Eptinezumab improved patient-reported outcomes in patients with migraine and medication-overuse headache: Subgroup analysis of the randomized PROMISE-2 trial.
Starling AJ; Cowan RP; Buse DC; Diener HC; Marmura MJ; Hirman J; Brevig T; Cady R
Headache; 2023 Feb; 63(2):264-274. PubMed ID: 36633219
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of eptinezumab in patients with chronic migraine and medication-overuse headache: a randomized, double-blind, placebo-controlled study.
Yu S; Zhou J; Luo G; Xiao Z; Ettrup A; Jansson G; Florea I; Ranc K; Pozo-Rosich P
BMC Neurol; 2023 Dec; 23(1):441. PubMed ID: 38102535
[TBL] [Abstract][Full Text] [Related]
6. Eptinezumab for prevention of chronic migraine: A randomized phase 2b clinical trial.
Dodick DW; Lipton RB; Silberstein S; Goadsby PJ; Biondi D; Hirman J; Cady R; Smith J
Cephalalgia; 2019 Aug; 39(9):1075-1085. PubMed ID: 31234642
[TBL] [Abstract][Full Text] [Related]
7. Eptinezumab for the prevention of chronic migraine: efficacy and safety through 24 weeks of treatment in the phase 3 PROMISE-2 (Prevention of migraine via intravenous ALD403 safety and efficacy-2) study.
Silberstein S; Diamond M; Hindiyeh NA; Biondi DM; Cady R; Hirman J; Allan B; Pederson S; Schaeffler B; Smith J
J Headache Pain; 2020 Oct; 21(1):120. PubMed ID: 33023473
[TBL] [Abstract][Full Text] [Related]
8. Long-term (48 weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high-frequency episodic and chronic migraine in a real world: Results of the EARLY 2 study.
Barbanti P; Aurilia C; Cevoli S; Egeo G; Fofi L; Messina R; Salerno A; Torelli P; Albanese M; Carnevale A; Bono F; D'Amico D; Filippi M; Altamura C; Vernieri F;
Headache; 2021 Oct; 61(9):1351-1363. PubMed ID: 34309862
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2.
Lipton RB; Goadsby PJ; Smith J; Schaeffler BA; Biondi DM; Hirman J; Pederson S; Allan B; Cady R
Neurology; 2020 Mar; 94(13):e1365-e1377. PubMed ID: 32209650
[TBL] [Abstract][Full Text] [Related]
10. Patient-identified most bothersome symptom in preventive migraine treatment with eptinezumab: A novel patient-centered outcome.
Lipton RB; Dodick DW; Ailani J; McGill L; Hirman J; Cady R
Headache; 2021 May; 61(5):766-776. PubMed ID: 34013992
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of eptinezumab for migraine prevention in patients with two-to-four previous preventive treatment failures (DELIVER): a multi-arm, randomised, double-blind, placebo-controlled, phase 3b trial.
Ashina M; Lanteri-Minet M; Pozo-Rosich P; Ettrup A; Christoffersen CL; Josiassen MK; Phul R; Sperling B
Lancet Neurol; 2022 Jul; 21(7):597-607. PubMed ID: 35716692
[TBL] [Abstract][Full Text] [Related]
12. Effects of Intravenous Eptinezumab vs Placebo on Headache Pain and Most Bothersome Symptom When Initiated During a Migraine Attack: A Randomized Clinical Trial.
Winner PK; McAllister P; Chakhava G; Ailani J; Ettrup A; Krog Josiassen M; Lindsten A; Mehta L; Cady R
JAMA; 2021 Jun; 325(23):2348-2356. PubMed ID: 34128999
[TBL] [Abstract][Full Text] [Related]
13. Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1).
Ashina M; Saper J; Cady R; Schaeffler BA; Biondi DM; Hirman J; Pederson S; Allan B; Smith J
Cephalalgia; 2020 Mar; 40(3):241-254. PubMed ID: 32075406
[TBL] [Abstract][Full Text] [Related]
14. Eptinezumab for the Prevention of Episodic Migraine: Sustained Effect Through 1 Year of Treatment in the PROMISE-1 Study.
Smith TR; Janelidze M; Chakhava G; Cady R; Hirman J; Allan B; Pederson S; Smith J; Schaeffler B
Clin Ther; 2020 Dec; 42(12):2254-2265.e3. PubMed ID: 33250209
[TBL] [Abstract][Full Text] [Related]
15. Eptinezumab Demonstrated Efficacy in Sustained Prevention of Episodic and Chronic Migraine Beginning on Day 1 After Dosing.
Dodick DW; Gottschalk C; Cady R; Hirman J; Smith J; Snapinn S
Headache; 2020 Nov; 60(10):2220-2231. PubMed ID: 33165938
[TBL] [Abstract][Full Text] [Related]
16. Erenumab in the prevention of high-frequency episodic and chronic migraine: Erenumab in Real Life in Italy (EARLY), the first Italian multicenter, prospective real-life study.
Barbanti P; Aurilia C; Egeo G; Fofi L; Cevoli S; Colombo B; Filippi M; Frediani F; Bono F; Grazzi L; Salerno A; Mercuri B; Carnevale A; Altamura C; Vernieri F
Headache; 2021 Feb; 61(2):363-372. PubMed ID: 33337544
[TBL] [Abstract][Full Text] [Related]
17. Adding eptinezumab to brief patient education to treat chronic migraine and medication-overuse headache: Protocol for RESOLUTION-A phase 4, multinational, randomized, double-blind, placebo-controlled study.
Jensen RH; Schytz HW; Tassorelli C; Terwindt GM; Carlsen LN; Mittoux A; Østerberg O; Lipton RB; Tepper SJ; Blumenfeld A; Lundqvist C
Front Neurol; 2023; 14():1114654. PubMed ID: 36908606
[TBL] [Abstract][Full Text] [Related]
18. Patient-reported outcomes, health-related quality of life, and acute medication use in patients with a ≥ 75% response to eptinezumab: subgroup pooled analysis of the PROMISE trials.
Lipton RB; Charleston L; Tassorelli C; Brevig T; Hirman J; Cady R
J Headache Pain; 2022 Feb; 23(1):23. PubMed ID: 35130836
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of eptinezumab for migraine prevention in patients with prior preventive treatment failures: subgroup analysis of the randomized, placebo-controlled DELIVER study.
Ashina M; Lanteri-Minet M; Ettrup A; Christoffersen CL; Josiassen MK; Phul R; Sperling B; Pozo-Rosich P
Cephalalgia; 2023 May; 43(5):3331024231170807. PubMed ID: 37125484
[TBL] [Abstract][Full Text] [Related]
20. Impact of Baseline Characteristics on the Efficacy and Safety of Eptinezumab in Patients With Migraine: Subgroup Analyses of PROMISE-1 and PROMISE-2.
Martin V; Nagy AJ; Janelidze M; Giorgadze G; Hirman J; Cady R; Mehta L; Buse DC
Clin Ther; 2022 Mar; 44(3):389-402. PubMed ID: 35131090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
